Celera, Syrrx in Drug Discovery Partnership | GenomeWeb

NEW YORK, Dec. 12 – Celera Genomics and Syrrx said Wednesday they had formed a drug discovery research collaboration.

Structural genomics company Syrrx said it would use its technology for determining a protein’s structure to uncover the 3-D make-up of proteins Celera identifies as potential drug targets.

Celera said it would use the information generated through the collaboration to discover small molecule drugs. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.